BUZZ-Kintara Therapeutics doubles on plans to merge with TuHURA Biosciences

Reuters04-03

** Shares of Kintara Therapeutics more than double to $0.21 premarket

** Co to merge with privately held TuHURA Biosciences, with merger expected to close in Q3

** KTRA equityholders expected to collectively own up to ~2.85%, or ~5.45% if certain milestones are met, while TuHURA equityholders are expected to collectively own ~97.15%, or 94.55% if the milestones are met

** TuHURA expects its experimental cancer vaccine to enter a late-stage trial as adjunct therapy with Merck's cancer drug Keytruda, with enrollment in the study to start in H2

The combined company is expected to operate under the name "TuHURA Biosciences, Inc." and to trade on Nasdaq under the ticker "HURA"

** Up to last close, KTRA stock down 40.8% YTD

(Reporting by Puyaan Singh)

((Puyaan.Singh@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment